Cantor Fitzgerald’s virtual panel on “Emerging Targets in Development for Inflammatory Bowel Disease (IBD)”
Events
Biomica To Present at Jefferies Microbiome-Based Therapeutics Summit, on April 22nd, 2021 (Virtual Conference)
Press Releases
Rehovot, Israel – April 19, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced that Dr. Elran Haber, Chief Executive Officer of Biomica, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday,
Jefferies Microbiome-Based Therapeutics summit
Events
Biomica Announces Positive Pre-Clinical Results, Demonstrating Efficacy of BMC128 in Melanoma
Press Releases
Biomica’s live biotherapeutic drug candidate, BMC128, significantly increased anti-tumor activity in combination with Immune Checkpoint Inhibitors in Melanoma. First-in-human, proof of concept study expected later this year
Rehovot, Israel – April 13, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.
Future of the Microbiome
Events
H.C. Wainwright Global Life Sciences Conference
Events
Chardan’s virtual 3rd Annual Microbiome Medicines Summit
Events
Crohn’s & Colitis Congress
Events
Biomica Announces Participation at the Crohn’s & Colitis Congress® January 21-24, 2021 (Virtual Conference)
Press Releases
Rehovot, Israel – January 21, 2020 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), today announced it will be featured as a presenting company at the Crohn’s & Colitis Congress® to be held from today January 21-24,
5th Microbiome Movement Drug Development Europe Conference
Events